Consumer Preference and Willingness to Pay for Direct-to-Consumer Mobile Teledermoscopy Services in Australia.
Cancer
Choice experiment
Dermoscopy
Melanoma
Questionnaire
Teledermoscopy
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
01
2021
accepted:
18
04
2021
pubmed:
14
9
2021
medline:
15
3
2022
entrez:
13
9
2021
Statut:
ppublish
Résumé
To investigate consumer preference and willingness to pay for mobile teledermoscopy services in Australia. Consumers who were taking part in a randomised controlled trial comparing mobile teledermoscopy and skin self-examination were asked to complete a survey which incorporated a discrete choice experiment (DCE) and a contingent valuation question. Responses were used to determine their willingness to pay for mobile teledermoscopy services in Australia and their overall service preferences. The 199 consumers who responded were 71% female and had a mean age of 42 years (range, 18-73). The DCE results showed that consumers prefer a trained medical professional to be involved in their skin cancer screening. Consumers were willing to pay AUD 41 to change from a general practitioner reviewing their lesions in-person to having a dermatologist reviewing the teledermoscopy images. Additionally, they were willing to pay for services that had shorter waiting times, that reduced the time away from their usual activities, and that have higher accuracy and lower likelihood of unnecessary excision of a skin lesion. When asked directly about their willingness to pay for a teledermoscopy service using a contingent valuation question, the majority (73%) of consumers selected the lowest two value brackets of AUD 1-20 or AUD 21-40. Consumers are willing to pay out of pocket to access services with attributes such as a dermatologist review, improved accuracy, and fewer excisions.
Identifiants
pubmed: 34515087
pii: 000517257
doi: 10.1159/000517257
pmc: PMC8985042
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
358-367Informations de copyright
© 2021 The Author(s) Published by S. Karger AG, Basel.
Références
Value Health. 2016 Jun;19(4):300-15
pubmed: 27325321
J Telemed Telecare. 2016 Jan;22(1):39-46
pubmed: 26026184
Health Econ. 2012 Feb;21(2):145-72
pubmed: 22223558
Br J Dermatol. 2016 Dec;175(6):1301-1310
pubmed: 27037999
Pharmacoeconomics. 2004;22(11):691-700
pubmed: 15250748
Cochrane Database Syst Rev. 2018 Dec 04;12:CD013193
pubmed: 30521686
J Telemed Telecare. 2018 Dec;24(10):683-689
pubmed: 30343653
Health Econ. 2004 Sep;13(9):901-7
pubmed: 15362181
Dermatology. 2020;236(2):90-96
pubmed: 32114570
J Telemed Telecare. 2019 Aug;25(7):438-444
pubmed: 29933722
JAMA Dermatol. 2017 Mar 1;153(3):319-327
pubmed: 27926766
JAMA Dermatol. 2015 May;151(5):489-96
pubmed: 25629626
Lancet Digit Health. 2020 Mar;2(3):e129-e137
pubmed: 33334577
JAMA Dermatol. 2018 Jun 1;154(6):694-700
pubmed: 29801161
BMJ. 2000 Jun 3;320(7248):1530-3
pubmed: 10834905
Dermatology. 2019;235(1):4-10
pubmed: 30404081
J Telemed Telecare. 2017 Oct;23(9):792-796
pubmed: 27789615
Health Econ. 2007 Aug;16(8):827-40
pubmed: 17238222
Dermatology. 2019;235(1):11-18
pubmed: 30404085
J Telemed Telecare. 2017 Jan;23(1):19-25
pubmed: 26729755
Br J Dermatol. 2014 Jan;170(1):20-30
pubmed: 24116870
Acta Derm Venereol. 2020 Apr 21;100(8):adv00117
pubmed: 32179927
Br J Dermatol. 2013 Jan;168(1):136-44
pubmed: 22612718
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1601-1608
pubmed: 32031277